Aura Biosciences, Inc. (NASDAQ:AURA) Holdings Lifted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 2.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 138,356 shares of the company’s stock after purchasing an additional 3,612 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.28% of Aura Biosciences worth $1,233,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Long Focus Capital Management LLC lifted its holdings in Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after acquiring an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. lifted its holdings in shares of Aura Biosciences by 194.5% during the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after purchasing an additional 41,711 shares during the period. Bank of New York Mellon Corp increased its stake in Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after purchasing an additional 48,549 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Aura Biosciences by 26.3% in the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after purchasing an additional 15,000 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. The trade was a 15.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 79,081 shares of company stock valued at $891,353. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Trading Down 2.5 %

NASDAQ AURA opened at $8.67 on Wednesday. Aura Biosciences, Inc. has a 1-year low of $6.63 and a 1-year high of $12.38. The firm’s fifty day simple moving average is $9.71 and its 200-day simple moving average is $8.76. The company has a market capitalization of $433.08 million, a PE ratio of -5.01 and a beta of 0.26.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. As a group, analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Wall Street Analyst Weigh In

AURA has been the subject of several recent analyst reports. BTIG Research raised their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. JMP Securities raised their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Finally, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.